share_log

JMP Securities Reiterates Market Outperform on Larimar Therapeutics, Maintains $25 Price Target

Benzinga ·  Mar 15 10:37

JMP Securities analyst Jonathan Wolleben reiterates Larimar Therapeutics (NASDAQ:LRMR) with a Market Outperform and maintains $25 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment